Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

Chihiro Murano; Akira Igarashi; Keiko Yamauchi; Sumito Inoue; Masafumi Watanabe

doi:10.17179/excli2019-1786

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

EXCLI J. 2019 Oct 7:18:893-898. doi: 10.17179/excli2019-1786. eCollection 2019.

Authors

Chihiro Murano¹, Akira Igarashi², Keiko Yamauchi², Sumito Inoue², Masafumi Watanabe²

Affiliations

¹ Postgraduate Clinical Training Center, Yamagata University Hospital, Yamagata, Japan.
² Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, Yamagata, Japan.

Abstract

A 20-year-old woman was diagnosed with stage 4 lung adenocarcinoma with an epidermal growth factor receptor (EGFR) exon 20 insertion gene mutation. Although the patient underwent chemotherapy, her lesions progressed. Liquid biopsy for EGFR T790M mutation showed negative results. After administering osimertinib, reduction of the lesions at the primary site was observed, and the patient's respiratory condition improved. Previous reports showing successful treatment of EGFR exon 20 insertion-positive lung adenocarcinoma with the standard osimertinib dose of 80 mg are limited. The present case demonstrated that osimertinib could be a possible treatment option for EGFR exon 20 insertion-positive lung adenocarcinoma.

Keywords: EGFR exon 20 insertion gene mutation; adenocarcinoma; lung cancer; osimertinib.

Publication types

Case Reports